| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8906410 | EIRGEN | Oral dosage form of 25-hydroxyvitamin D |
Feb, 2027
(3 years from now) | |
| US10213442 | EIRGEN | Treating vitamin D insufficiency and deficiency with 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 |
Feb, 2027
(3 years from now) | |
| US9943530 | EIRGEN | Treating vitamin D insufficiency and deficiency with 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 |
Feb, 2027
(3 years from now) | |
| US9925147 | EIRGEN | Method for treating secondary hyperparathyroidism in CKD |
Apr, 2028
(4 years from now) | |
| US11154509 | EIRGEN | Methods for controlled release oral dosage of a vitamin D compound |
Apr, 2028
(4 years from now) | |
| US9498486 | EIRGEN | Method for controlled release oral dosage of a vitamin D compound |
Apr, 2028
(4 years from now) | |
| US8207149 | EIRGEN | Method for treating secondary hyperparathyroidism in CKD |
Apr, 2028
(4 years from now) | |
| US8778373 | EIRGEN | Methods for controlled release oral dosage of a vitamin D compound |
Apr, 2028
(4 years from now) | |
| US9408858 | EIRGEN | Method for treating secondary hyperparathyroidism in CKD |
Apr, 2028
(4 years from now) | |
| US8361488 | EIRGEN | Methods and compositions for controlled release oral dosage of a vitamin D compound |
Jul, 2028
(4 years from now) | |
| US8426391 | EIRGEN | Treating vitamin D insufficiency and deficiency with 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 |
Aug, 2028
(4 years from now) | |
| US11253528 | EIRGEN | Stabilized modified release Vitamin D formulation and method of administering same |
Mar, 2034
(10 years from now) | |
| US10357502 | EIRGEN | Stabilized modified release vitamin D formulation and method of administering same |
Mar, 2034
(10 years from now) | |
| US9861644 | EIRGEN | Stabilized modified release vitamin D formulation and method of administering same |
Mar, 2034
(10 years from now) | |
| US10300078 | EIRGEN | Stabilized modified release vitamin D formulation and method of administering same |
Mar, 2034
(10 years from now) | |
Rayaldee is owned by Eirgen.
Rayaldee contains Calcifediol.
Rayaldee has a total of 15 drug patents out of which 0 drug patents have expired.
Rayaldee was authorised for market use on 17 June, 2016.
Rayaldee is available in capsule, extended release;oral dosage forms.
Rayaldee can be used as administration of 25-hydroxyvitamin d3 by controlled release, use of controlled release 25-hydroxyvitamin d in treating secondary hyperparathyroidism in patients having chronic kidney disease, treatment of secondary hyperparathyroidism in patients with stage 3 or 4 chronic kidney disease using controlled release, oral 25-hydroxyvitamin d, use of sustained release 25-hydroxyvitamin d in treating patients having 25-hydroxyvitamin d insufficiency or deficiency, treating secondary hyperparathyroidism in stage 3/4 chronic kidney disease with sustained release 25-hydroxyvitamin d to reduce the patient's serum parathyroid hormone level while avoiding pth oversuppression, use of extended release oral 25-hydroxyvitamin d3 in treating secondary hyperparathyroidism in adult patients having chronic kidney disease stage 3 or stage 4, maintaining serum 25-hydroxyvitamin d at a level of at least 30 ng/ml with oral, sustained release 25-hydroxyvitamin d, treating secondary hyperparathyroidism in ckd with sustained release calcifediol to reduce the patient's serum parathyroid hormone level and cmax24hr/c24hr is reduced compared to bolus iv injection and immediate-release, oral dosing; treating secondary hyperparathyroidism in chronic kidney disease with sustained release 25-hydroxyvitamin d to reduce the patient's serum parathyroid hormone level and the sustained release is over at least 10 hours; treating secondary hyperparathyroidism in chronic kidney disease with sustained release 25-hydroxyvitamin d to reduce the patient's serum parathyroid hormone level and cmax is reduced compared to bolus iv injection and immediate-release, oral dosing; treating shpt in ckd with sustained release calcifediol to reduce serum parathyroid hormone level and change in serum concentration of calcifediol in dose interval is reduced compared to bolus iv injection and immediate-release, oral dosing; treating secondary hyperparathyroidism in ckd with sustained release calcifediol to reduce the patient's serum parathyroid hormone level and tmax is increased compared to bolus iv injection and immediate-release, oral dosing.
The generics of Rayaldee are possible to be released after 14 March, 2034.
Drugs and Companies using CALCIFEDIOL ingredient
Market Authorisation Date: 17 June, 2016
Treatment: Maintaining serum 25-hydroxyvitamin d at a level of at least 30 ng/ml with oral, sustained release 25-hydroxyvitamin d; Treating secondary hyperparathyroidism in ckd with sustained release calcifediol...
Dosage: CAPSULE, EXTENDED RELEASE;ORAL
RAYALDEE family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic